Sorafenib and Everolimus for paediatric patients with unresectable osteosarcoma

Sorafenib and Everolimus for paediatric patients with unresectable osteosarcoma

Bibliographic Details
Main Authors:	Shilpa Vijayasrinivasan, Chetan Dhamne
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Series:	Pediatric Hematology Oncology Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468124517302449

Similar Items

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
by: Noritoshi Kobayashi, et al.
Published: (2016-02-01)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/− Mice Is Superior to Everolimus Alone
by: Jian Yang, et al.
Published: (2017-02-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
by: Mahvash A, et al.
Published: (2016-02-01)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
by: Chris Coppin
Published: (2010-04-01)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
by: Debora L. S. Danilovic, et al.
Published: (2018-05-01)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
by: Ying Wu, et al.
Published: (2020-07-01)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
by: Teyateeti A, et al.
Published: (2020-09-01)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
by: Sheng-Long Ye, et al.
Published: (2018-03-01)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
by: Laura Marconato, et al.
Published: (2020-05-01)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
by: Chao, Y., et al.
Published: (2022)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
by: Lei Zhang, et al.
Published: (2020-09-01)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2019-08-01)

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2021-08-01)

A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
by: James Coventon
Published: (2017-09-01)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
by: Hung-Wei Wang, et al.
Published: (2021-07-01)

High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
by: Emanuela Palmerini, et al.
Published: (2020-10-01)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Lin Li, et al.
Published: (2018-09-01)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
by: Lei Zhang, et al.
Published: (2021-05-01)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by: Jaejun Lee, et al.
Published: (2020-12-01)

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment
by: Lucia Nogova, et al.
Published: (2020-07-01)

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
by: Lei Zhang, et al.
Published: (2021-08-01)

Central Telangiectatic Osteosarcoma of the Mandible in a Paediatric Patient: A Rarity
by: Divya Tomar, et al.
Published: (2016-12-01)

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
by: Breder, V., et al.
Published: (2022)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
by: Ruben Mujica-Mota, et al.
Published: (2018-09-01)

Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis
by: ZHENG Kang, et al.
Published: (2016-05-01)

Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
by: Sheng-Long Ye, et al.
Published: (2017-03-01)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
by: Alexander Chehrazi-Raffle, et al.
Published: (2020-06-01)

The use of everolimus in renal-transplant patients
by: Julio Pascual
Published: (2009-06-01)

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
by: Shukui Qin, et al.
Published: (2021-04-01)

Everolimus in kidney transplantation
by: Cooper JE, et al.
Published: (2011-07-01)

Low-Grade Surface Osteosarcoma of the Temporal Bone in Paediatric Patients: A Case Report and Literature Review
by: Noémie Villemure-Poliquin, et al.
Published: (2019-06-01)

Natural History of Patients with Unresectable Cholangiocarcinoma
by: Sudhakar A., et al.
Published: (2019-10-01)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
by: Paul E. Oberstein, et al.
Published: (2012-01-01)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
by: Paul E. Oberstein, et al.
Published: (2012-01-01)

Long-term outcome of everolimus treatment in transplant patients
by: Salvadori M, et al.
Published: (2011-05-01)

Cannot write session to /tmp/vufind_sessions/sess_dvetvniitoarrd56v0jl5bo3fn